Figure 3
Figure 3. Tolerant Des-TCR CD8 T cells fail to acquire effector function after LIP. (A) Seven to 10 days after transfer of 2 × 106 splenocytes from thymectomized Des-TCR × 2.4KerIV-Kb.RAG2−/− (tolerant) and thymectomized Des-TCR.RAG2−/− (reactive) donor mice into RAG2−/− mice host splenocytes were restimulated in vitro for 6 hours with anti-CD3 antibody (4 μg/mL). Des-TCR CD8 T cells were analyzed for intracellular IFN-γ production by flow cytometry. Shown are relative log fluorescence intensities for CD8 and IFN-γ. Representative diagrams are depicted; numbers indicate mean percentages of IFN-γ–positive CD8 T cells (0.5% ± 0.7% versus 9.3% ± 7.6%; P < .01) and were pooled from 3 independent experiments (n = 8). (B) In vivo kill assay of Kb-tolerant and Kb-reactive Des-TCR CD8 T cells (2 × 106 splenocytes per mouse) analyzed 10 days after T-cell transfer into RAG2−/− mice. Splenocytes from CBA and CBK mice were used as targets (control = RAG2−/− mice without transfer). The data were pooled from 2 separate experiments (*P < .05; n = 8 per group). (C) Splenocytes (2 × 106) from Kb-tolerant and Kb-reactive donor mice were transferred intravenously into RAG2−/− mice, which were challenged subcutaneously with P815.Kb.B7 tumor cells 3 days later (see Table 1). Representative tumor growth curves of 4 individual mice per group are shown. Data are representative for 3 independent experiments. (D) Splenocytes (2 × 106) from tolerant and reactive donor mice (as above) were transferred intravenously into RAG2−/− mice. Ten days later recipient splenocytes were restimulated in vitro with αCD3 (4 μg/mL), αCD3, and αCD28 (2 and 4 μg/mL) or irradiated C57BL/6 splenocytes (B6), and 3H-thymidine incorporation was measured after 4 days of culture.

Tolerant Des-TCR CD8 T cells fail to acquire effector function after LIP. (A) Seven to 10 days after transfer of 2 × 106 splenocytes from thymectomized Des-TCR × 2.4KerIV-Kb.RAG2−/− (tolerant) and thymectomized Des-TCR.RAG2−/− (reactive) donor mice into RAG2−/− mice host splenocytes were restimulated in vitro for 6 hours with anti-CD3 antibody (4 μg/mL). Des-TCR CD8 T cells were analyzed for intracellular IFN-γ production by flow cytometry. Shown are relative log fluorescence intensities for CD8 and IFN-γ. Representative diagrams are depicted; numbers indicate mean percentages of IFN-γ–positive CD8 T cells (0.5% ± 0.7% versus 9.3% ± 7.6%; P < .01) and were pooled from 3 independent experiments (n = 8). (B) In vivo kill assay of Kb-tolerant and Kb-reactive Des-TCR CD8 T cells (2 × 106 splenocytes per mouse) analyzed 10 days after T-cell transfer into RAG2−/− mice. Splenocytes from CBA and CBK mice were used as targets (control = RAG2−/− mice without transfer). The data were pooled from 2 separate experiments (*P < .05; n = 8 per group). (C) Splenocytes (2 × 106) from Kb-tolerant and Kb-reactive donor mice were transferred intravenously into RAG2−/− mice, which were challenged subcutaneously with P815.Kb.B7 tumor cells 3 days later (see Table 1). Representative tumor growth curves of 4 individual mice per group are shown. Data are representative for 3 independent experiments. (D) Splenocytes (2 × 106) from tolerant and reactive donor mice (as above) were transferred intravenously into RAG2−/− mice. Ten days later recipient splenocytes were restimulated in vitro with αCD3 (4 μg/mL), αCD3, and αCD28 (2 and 4 μg/mL) or irradiated C57BL/6 splenocytes (B6), and 3H-thymidine incorporation was measured after 4 days of culture.

Close Modal

or Create an Account

Close Modal
Close Modal